Patrick Wen, MD

Dr Patrick Wen discusses the FDA approval of dordaviprone, highlighting its potential to improve outcomes for patients with challenging brain tumors.

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making it the first approved systemic therapy for this rare disease.